Worrisome findings from the US Food and Drug Administration's first inspections of drug manufacturing facilities around the world helped drive a surge in warning letters in fiscal year 2019, according to the agency's drug manufacturing quaility director.
These letters went to firms making OTC drugs and targeted inadequate testing of raw materials and components, and failure to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?